195 related articles for article (PubMed ID: 21751166)
21. Recombinant human thyrotropin stimulation prior to
Azorín Belda MJ; Martínez Caballero A; Figueroa Ardila GC; Martínez Ramírez M; Gómez Jaramillo CA; Dolado Ardit JI; Verdú Rico J
Rev Esp Med Nucl Imagen Mol; 2017; 36(1):7-12. PubMed ID: 27422154
[TBL] [Abstract][Full Text] [Related]
22. Graves' disease radioiodine-therapy: choosing target absorbed doses for therapy planning.
Willegaignon J; Sapienza MT; Coura-Filho GB; Watanabe T; Traino AC; Buchpiguel CA
Med Phys; 2014 Jan; 41(1):012503. PubMed ID: 24387527
[TBL] [Abstract][Full Text] [Related]
23. Vitamin B12 levels are not affected by radioiodine ablation of the thyroid.
Potham SK; Vaikkakara S; Sachan A; Rao SP; Kalawat TC; Ravi P; Sunil E; Rajitha D; Arun M; Sailaja A
Endocr Regul; 2014 Apr; 48(2):77-85. PubMed ID: 24824803
[TBL] [Abstract][Full Text] [Related]
24. Administration of a single dose of recombinant human thyrotrophin enhances the efficacy of radioiodine treatment of large compressive multinodular goitres.
Silva MN; Rubió IG; Romão R; Gebrin EM; Buchpiguel C; Tomimori E; Camargo R; Cardia MS; Medeiros-Neto G
Clin Endocrinol (Oxf); 2004 Mar; 60(3):300-8. PubMed ID: 15008994
[TBL] [Abstract][Full Text] [Related]
25. Radioiodine treatment of hyperthyroidism-prognostic factors for outcome.
Allahabadia A; Daykin J; Sheppard MC; Gough SC; Franklyn JA
J Clin Endocrinol Metab; 2001 Aug; 86(8):3611-7. PubMed ID: 11502786
[TBL] [Abstract][Full Text] [Related]
26. Predictive Value of a Thyroid-Absorbed Dose with a Shorter Effective Half-Life on Efficacy in Graves Disease Patients Receiving Iodine-131 Therapy.
Yu F; Zhang R; Zhang G; Meng Z; Liu X; He Y; Tan J; Wang R
Med Sci Monit; 2021 Jan; 27():e928796. PubMed ID: 33497370
[TBL] [Abstract][Full Text] [Related]
27. Correlation of radioiodine doses for 6-hr and 24-hour iodine-131 thyroid uptake values for Graves' hyperthyroidism.
Horn-Lodewyk J
Endocr J; 2019 Dec; 66(12):1047-1052. PubMed ID: 31391354
[TBL] [Abstract][Full Text] [Related]
28. Optimized radioiodine therapy of Graves' disease: analysis of the delivered dose and of other possible factors affecting outcome.
Catargi B; Leprat F; Guyot M; Valli N; Ducassou D; Tabarin A
Eur J Endocrinol; 1999 Aug; 141(2):117-21. PubMed ID: 10427153
[TBL] [Abstract][Full Text] [Related]
29. Predictors of euthyreosis in hyperthyroid patients treated with radioiodine
Stachura A; Gryn T; Kałuża B; Budlewski T; Franek E
BMC Endocr Disord; 2020 Jun; 20(1):77. PubMed ID: 32487052
[TBL] [Abstract][Full Text] [Related]
30. Iodine isotope ¹³¹I therapy for toxic nodular goitre: treatment efficacy parameters.
Szumowski P; Rogowski F; Abdelrazek S; Kociura-Sawicka A; Sokolik-Ostasz A
Nucl Med Rev Cent East Eur; 2012 Apr; 15(1):7-13. PubMed ID: 23047567
[TBL] [Abstract][Full Text] [Related]
31. Radioiodine therapy of benign thyroid disorders: what are the effective thyroidal half-life and uptake of 131I?
Kobe C; Eschner W; Wild M; Rahlff I; Sudbrock F; Schmidt M; Dietlein M; Schicha H
Nucl Med Commun; 2010 Mar; 31(3):201-5. PubMed ID: 19907353
[TBL] [Abstract][Full Text] [Related]
32. Comparison of different thyroid committed doses in radioiodine therapy for Graves' hyperthyroidism.
Grosso M; Traino A; Boni G; Banti E; Della Porta M; Manca G; Volterrani D; Chiacchio S; AlSharif A; Borsò E; Raschillà R; Di Martino F; Mariani G
Cancer Biother Radiopharm; 2005 Apr; 20(2):218-23. PubMed ID: 15869459
[TBL] [Abstract][Full Text] [Related]
33. [Therapeutic results of radioiodine therapy of hyperthyroid thyroid gland diseases].
Debrand-Passard A; Barzen G; Richter W; Wenzel KW; Felix R
Med Klin (Munich); 1994 Jun; 89(6):319-23. PubMed ID: 8072455
[TBL] [Abstract][Full Text] [Related]
34. Thyroid uptake of radioactive iodine in hyperthyroidism.
Hooper PL; Caplan RH
JAMA; 1977 Aug; 238(5):411-3. PubMed ID: 577556
[TBL] [Abstract][Full Text] [Related]
35. Radioiodine therapy in Graves' disease based on tissue-absorbed dose calculations: effect of pre-treatment thyroid volume on clinical outcome.
Reinhardt MJ; Brink I; Joe AY; Von Mallek D; Ezziddin S; Palmedo H; Krause TM
Eur J Nucl Med Mol Imaging; 2002 Sep; 29(9):1118-24. PubMed ID: 12192554
[TBL] [Abstract][Full Text] [Related]
36. Radioiodine therapy in hyperthyroidism: inverse correlation of pretherapeutic iodine uptake level and post-therapeutic outcome.
Walter MA; Christ-Crain M; Eckard B; Schindler C; Nitzsche EU; Müller-Brand J; Müller B
Eur J Clin Invest; 2004 May; 34(5):365-70. PubMed ID: 15147334
[TBL] [Abstract][Full Text] [Related]
37. Effects of radioiodine therapy in hyperthyroidism (thyroid function, thyroid volume, Graves' ophtalmopathy, thyrotoxic heart disease).
Ursu HI; Dumitriu L; Grigorie D; Simescu M; Vaida E; Belgun M; Popovici D
Rom J Endocrinol; 1993; 31(3-4):155-63. PubMed ID: 7697064
[TBL] [Abstract][Full Text] [Related]
38. Long-term results of two schedules of radioiodine treatment for toxic multinodular goitre.
Huysmans DA; Hermus AR; Corstens FH; Kloppenborg PW
Eur J Nucl Med; 1993 Nov; 20(11):1056-62. PubMed ID: 8287873
[TBL] [Abstract][Full Text] [Related]
39. The effect of short-term treatment with lithium carbonate on the outcome of radioiodine therapy in patients with long-lasting Graves' hyperthyroidism.
Sekulić V; Rajić M; Vlajković M; Ilić S; Stević M; Kojić M
Ann Nucl Med; 2017 Dec; 31(10):744-751. PubMed ID: 28895066
[TBL] [Abstract][Full Text] [Related]
40. Clinical outcome of radioiodine treatment of hyperthyroidism: a follow-up study.
Berg G; Michanek A; Holmberg E; Nyström E
J Intern Med; 1996 Feb; 239(2):165-71. PubMed ID: 8568485
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
